Physician profile
Arnel Castrence
NPI 1225092968
$490.61
in general payments reported to CMS, 2019-2025
15 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.69 · 2024: $132 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $83.04 | 2019-2025 | Airsupra |
| Amgen INC. | $66.52 | 2025 | Repatha, Otezla |
| Advanced Oxygen Therapy INC. | $50.00 | 2024 | Topical Oxygen Chamber For Extremities |
| Dynavax Technologies Corporation | $38.62 | 2024 | Heplisav-B |
| Abbvie INC. | $36.16 | 2025 | |
| Tactile Systems Technology INC | $30.55 | 2025 | Flexitouch Plus, Nimbl |
| Medtronic, INC. | $24.50 | 2024 | Intellis Adaptivestim |
| Neurocrine Biosciences, INC. | $24.43 | 2025 | |
| Lilly USA, LLC | $22.82 | 2025 | Zepbound, Mounjaro |
| Globus Medical, INC. | $21.28 | 2025 | Senza |
| Novo Nordisk INC | $20.64 | 2025 | Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $20.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.54 | 2025 | |
| Shire North American Group INC | $17.53 | 2019 | |
| Exact Sciences Corporation | $15.74 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnel Castrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.